Conmed CORP 10-Q quarterly reports

CONMED Corporation announced its second quarter 2026 financial results, showing modest revenue growth driven by its Orthopedic Surgery segment, while navigating strategic divestitures and debt management.

CONMED Corporation announced its first quarter 2026 financial results, reporting a slight decrease in net sales driven by the exit from certain gastroenterology product lines, while gross profit margins improved.

CONMED Corporation reported increased net sales for Q3 2025 and the nine months ended September 30, 2025, but experienced significant declines in net income and gross profit margins due to higher costs, inventory write-offs, and advisory/consulting fees.

CONMED Corporation reported a significant drop in second-quarter net income and diluted EPS despite modest revenue growth, primarily due to increased selling and administrative expenses and unfavorable contingent consideration adjustments.

CONMED Corporation's Q1 2025 net sales increased by 2.9% year-over-year, but net income significantly decreased.

CONMED Corporation's third quarter results show a significant increase in net income and improved gross profit margins, driven by growth in both orthopedic and general surgery product lines.

CONMED Corporation's Q2 2024 results show a significant increase in net income and gross profit margin, driven by strong performance in the general surgery product line.

CONMED Corporation's first quarter 2024 results show a significant increase in net income and improved gross profit margins compared to the same period last year.